Janux Therapeutics CEO To Provide Update On JANX007 Primarily Focused On Phase 1a Dose Escalation Data And Secondarily On Phase 1b Expansion Data In Adult Subjects With mCRPC
Benzinga Newsdesk 11 months ago
News
The virtual event will take place on Monday, December 1, 2025, at 4:30 PM ETJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies
The virtual event will take place on Monday, December 1, 2025, at 4:30 PM ET
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced it will host a virtual event on Monday, December 1, 2025, at 4:30 PM ET.
David Campbell, Ph.D., President & Chief Executive Officer will provide an update on JANX007 primarily focused on Phase 1a dose escalation data and secondarily on Phase 1b expansion data in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).